Latest Tyrosine kinase receptors Stories
Molecularly targeted therapies can reduce tumors rapidly.
CAMBRIDGE, Mass., July 22 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc.
MM-111 antibody uses HER2 target to reach and block HER3.
RIDGEFIELD, Conn., May 20 /PRNewswire/ -- Boehringer Ingelheim will announce preliminary data in the areas of head and neck cancer and non-small cell lung cancer (NSCLC) for one of the company's investigational compounds, BIBW 2992.
CAMBRIDGE, Mass., April 30 /PRNewswire/ -- Merrimack Pharmaceuticals' MM-111 Team Leader Charlotte McDonagh, Ph.D., will discuss the development of this novel, bispecific antibody on Tuesday, May 4, at the BIO 2010 International Convention in Chicago, Illinois.
Levels of epidermal growth factor receptor (EGFR) may be elevated in the blood of women within 17 months prior to their breast cancer diagnosis.
Stanford University School of Medicine researchers have identified several small molecules that mimic a key but cumbersome protein in the brain, a discovery that could open the door to new therapies for a variety of brain disorders.
Altered expression and/or function of the protein BDNF, which promotes nerve cell survival, generation, and function, have been implicated in several neurodegenerative conditions, including Alzheimer disease.
CAMBRIDGE, Mass., Feb. 22 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the first patient has received an initial dose in a Phase 1/2 clinical study combining MM-121 with Tarceva(Â®) (erlotinib) in patients with non-small cell lung cancer (NSCLC).
A team of researchers, led by Patrick Mehlen, at UniversitÃ© de Lyon, France, has identified the protein NT-3 and the cell-surface molecule to which it binds (TrkC) as potential therapeutic targets for the treatment of neuroblastoma â€” the most frequent solid tumor in young childrenâ€” by studying human neuroblastoma cells in vitro and after xenotransplantation into mice and chicks.
- A hairdresser.